Targeting angiogenesis in renal cell carcinoma

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 16, 2013, Pages 2221-2236

  Posadas, Edwin M ^a   Limvorasak, Suwicha ^a   Sharma, Shaleekha ^a   Figlin, Robert A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

angiogenesis; angiopoietin; FGFR; kidney cancer; MET; mTOR; PI3K; VEGF

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; APITOLISIB; AXITINIB; AZD 2014; BIOLOGICAL MARKER; BRIVANIB; BUPARLISIB; CABOZANTINIB; CC 223; CEDIRANIB; CRIZOTINIB; DOVITINIB; EVEROLIMUS; FORETINIB; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NESVACUMAB; NINTEDANIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SAR 307746; SORAFENIB; SUNITINIB; TCR 105; TEMSIROLIMUS; TIVANTINIB; TIVOZANIB; TK 1258; TRC 105; TREBANANIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG USE; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY CARCINOMA; LIVER TOXICITY; MOOD CHANGE; MOOD DISORDER; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL EDEMA; PNEUMONIA; PROTEIN TARGETING; PRURITUS; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; TASTE DISORDER; TELANGIECTASIA; UPREGULATION; VOMITING; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84885656672     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.832202     Document Type: Review

References (123)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
2. Richard S, Gardie B, Couve S, et al. How a rare disease illuminates cancer biology. Semin Cancer Biol 2013;23(1):26-37
3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)
4. USFDA. Approval Letter- Sunitinib (January 2006). 2006
5. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial gro
6. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178(5):1883-7 (Pubitemid 47538608)
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
8. Molina AM, Jia X, Feldman DR, et al. Long-Term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 2013; [Epub ahead of print]
9. Patil S, Figlin RA, Hutson TE, et al. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-alpha. Br J Cancer 2012;106(10):1587-90
10. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics 1989;45(3):781-95 (Pubitemid 19249321)
11. Goldhirsch A, Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989;7(1):36-44 (Pubitemid 19089079)
12. Gelber RD, Goldhirsch A. Comparison of adjuvant therapies using quality-of-life considerations. Int J Technol Assess Health Care 1989;5(3):401-13
13. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287-96
14. Sternberg CN. Pazopanib in renal cell carcinoma. Clin Adv Hematol Oncol 2010;8(4):232-3
15. Motzer R, Hutson TE, Reeves J, et al. Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. Ann Oncol 2012;23(9):abstract LBA8
16. Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol 2012;30(Suppl): abstract CRA4502
17. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30(12):1371-7
18. Najjar Y, Elson P, Wood L, et al. Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma. J Clin Oncol 2013;31(Suppl):abstract e 15534
19. Rini BI, Wood LS, Elson P, et al. A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;31(Suppl):abstract 4515
20. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14(6):552-62
21. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
22. Hutson TE, Gallardo J, Lesovoy V, et al. Axitinib versus sorafenib as first line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;31(Suppl):abstract LBA348
23. Harshman LC, Kroeger N, Rha SY, et al. First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): an updated analysis from the International mRCC Database Consortium (IMDC). J Clin Oncol 2013;31(Suppl): abstract e15518
24. Motzer RJ, Barrios CH, Kim TM, et al. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;31(Suppl):abstract 4504
25. Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 2012;30(14):1678-85
26. Sternberg CN, Eisen T, Tomczak P, et al. Tivozanib in patients treatment-naive for metastatic renal cell carcinoma: a subset analysis of the phase III TIVO-1 study. J Clin Oncol 2013;31(Suppl):abstract 4513
27. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400 (Pubitemid 40775678)
28. Sridhar SS, Mackenzie MJ, Hotte SJ, et al. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs 2013;31(4):1008-15
29. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81 (Pubitemid 46849157)
30. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
31. Frost P, Berlanger E, Mysore V, et al. Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol 2013;2013:897025
32. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4(5):335-48 (Pubitemid 38579480)
33. Champion KJ, Guinea M, Dammai V, Hsu T. Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. Cancer Res 2008;68(12):4649-57
34. Zhang H, Berel D, Wang Y, et al. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS ONE 2013;8(1):e54918
35. Figlin RA, Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer 2013;133(4):788-96
36. Pike KG, Malagu K, Hummersone MG, et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013;23(5):1212-16
37. Banerji U, Dean EJ, Gonzalez M, et al. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors. J Clin Oncol 2012;30(Suppl):abstract 3004
38. Shih KC, Bendell JC, Reinert A, et al. Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. J Clin Oncol 2012;30(Suppl):abstract 3006
39. Varga A, Mita MM, Wu JJ, et al. Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors. J Clin Oncol 2013;31(Suppl):abstract 2606
40. Garcia-Martinez JM, Moran J, Clarke RG, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009;421(1):29-42
41. Serova M, de Gramont A, Tijeras-Raballand A, et al. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol 2013;71(5):1297-307
42. Koul D, Fu J, Shen R, et al. Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 2012;18(1):184-95
43. Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012;11(2):317-28
44. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3Kinhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30(3):282-90
45. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7(7):1851-63
46. Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(suppl):abstract 3005
47. Roulin D, Waselle L, Dormond-Meuwly A, et al. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer 2011;10:90
48. Nyfeler B, Chen Y, Li X, et al. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS ONE 2012;7(11):e48548
49. Sutherlin DP, Bao L, Berry M, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 2011;54(21):7579-87
50. Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011;10(12):2426-36
51. Makhov PB, Golovine K, Kutikov A, et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 2012;11(7):1510-17
52. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100(22):12718-23 (Pubitemid 37339965)
53. Hong SW, Jung KH, Lee HS, et al. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis 2013; [Epub ahead of print]
54. Hong SW, Jung KH, Park BH, et al. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Cancer Lett 2013;332(1):74-82
55. Lin YM, Huang YL, Fong YC, et al. Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway. PLoS One 2012;7(11):e50924
56. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70(24):10090-100
57. Jahangiri A, De Lay M, Miller LM, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013;19(7):1773-83
58. Ju L, Zhou C. Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell Int 2013;13(1):15
59. Goetsch L, Caussanel V, Corvaia N. Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. Front Biosci 2013;18:454-73
60. Yang H, Lee HW, Kim Y, et al. Radiosensitization of brain metastasis by targeting c-MET. Lab Invest 2013;93(3):344-53
61. Ogi S, Fujita H, Kashihara M, et al. Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs. Cancer Sci 2013;104(5):573-83
62. Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013;24(2):343-9
63. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298-308
64. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31(4):412-19
65. Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep 2013;15(2):76-82
66. Apolo AB, Parnes HL, Madan RA, et al. A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. J Clin Oncol 2013;31(Suppl):abstract TPS4589
67. Bentzien F, Zuzow M, Heald N, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 2013; [Epub ahead of print]
68. Durante C, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs 2011;20(3):407-13
69. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19):2660-6
70. Choueiri TK, Pal SK, Cabanillas ME, et al. Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC). J Clin Oncol 2011;29(Suppl):abstract e13042
71. Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69(20):8009-16
72. Shapiro GI, McCallum S, Adams LM, et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs 2013;31(3):742-50
73. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013;31(2):181-6
74. Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cellcarcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol 2012;25(11):1516-25
75. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9(6):1544-53
76. Katayama R, Aoyama A, Yamori T, et al. Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition. Cancer Res 2013;73(10):3087-96
77. Adjei AA, Schwartz B, Garmey E. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 2011;16(6):788-99
78. Rosen LS, Senzer N, Mekhail T, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011;17(24):7754-64
79. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 2012;118(23):5894-902
80. Puzanov I, Sosman JA, Santoro A, et al. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study. J Clin Oncol 2013;30(Suppl):abstract 4545
81. Auguste P, Javerzat S, Bikfalvi A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 2003;314(1):157-66 (Pubitemid 37409921)
82. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16(2):159-78 (Pubitemid 40616114)
83. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009;9(5):639-51
84. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309 (Pubitemid 41443415)
85. Welti JC, Gourlaouen M, Powles T, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011;30(10):1183-93
86. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68(12):4774-82
87. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16(1):311-19
88. Eisen T, Shparyk Y, Jones R, et al. Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients. J Clin Oncol 2013;31(Suppl):abstract 4506
89. Angevin E, Lopez-Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 2013;19(5):1257-68
90. Angevin E, Grünwald V, Ravaud A, et al. A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 2011;29(Suppl):abstract 4551
91. Motzer RJ, Porta C, Bjarnason GA, et al. Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies. J Clin Oncol 2012;30(Suppl):abstract TPS4683
92. Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14(19):6146-53
93. Cai ZW, Zhang Y, Borzilleri RM, et al. Discovery of brivanib alaninate (S)-(R)-1- (4-(4-fluoro-2-methyl-1H-indol-5-yloxy)- 5-methylpyrrolo[2,1-f][1,2, 4] triazin-6- yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008;51(6):1976-80 (Pubitemid 351438880)
94. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013;328(1):18-26
95. Robson EJ, Ghatage P. AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 2011;20(2):297-304
96. Shimamoto G, Gegg C, Boone T, Queva C. Peptibodies: a flexible alternative format to antibodies. MAbs 2012;4(5):586-91
97. Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010;16(11):3044-56
98. Peeters M, Strickland AH, Lichinitser M, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013;108(3):503-11
99. Eatock MM, Tebbutt NC, Bampton CL, et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol 2013;24(3):710-18
100. Rini B, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012;118(24):6152-61
101. Shah AA, Karzai F, Madan RA, et al. A phase II study of trebananib (AMG 386) and abiraterone in metastatic castration resistant prostate cancer. J Clin Oncol 2013;31(Suppl):TPS5102
102. Atkins MB, Ravaud A, Gravis G, et al. Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study. J Clin Oncol 2012;30(Suppl):abstract 4606
103. Papadopoulos KP, Sahebjam S, Kelley RK, et al. A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies. J Clin Oncol 2013;31(Suppl):abstract 2517
104. Rosen LS, Robert F, Matei D, et al. A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors. J Clin Oncol 2013;31(Suppl):abstract 3059
105. Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184(3):859-64
106. Karam JA, Devine CE, Lozano M, et al. A phase II clinical trial examining the impact of neoadjuvant axitinib on primary tumor response in patients with locally advanced clear cell renal cell carcinoma. J Clin Oncol 2013;31(Suppl):abstract 4516
107. Powles T, Sarwar N, Stockdale A, et al. Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: a clinical and biomarker study. J Clin Oncol 2013;31(suppl):abstract 4508
108. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73
109. Poprach A, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012;23(12):3137-43
110. Rixe O, Dutcher J, Motzer R, et al. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol 2009;27(15s):abstract 5045
111. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422-8
112. Rini BI, Halabi S, Taylor J, et al. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10(8):2584-6 (Pubitemid 38509129)
113. Nixon AB, Halabi S, Shterev I, et al. Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): results from CALGB 90206 (Alliance). J Clin Oncol 2013;31(Suppl):abstract 4520
114. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012;13(8):827-37
115. Zurita AJ, Jonasch E, Wang X, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;23(1):46-52
116. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883-92
117. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
118. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34 (Pubitemid 46089673)
119. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
120. Motzer RJ, Eisen T, Hutson TE, et al. Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. J Clin Oncol 2013;31(suppl):abstract 350
121. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 2012;30 (suppl):abstract 4501
122. Mulders P, Hawkins R, Nathan P, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer 2012;48(4):527-37
123. Eisen T, Shparyk Y, Jones R, et al. Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients. J Clin Oncol 2013;31(suppl):abstract 4506.